Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291512 | 0.97 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14258642 | 0.97 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1404135 | 0.92 | — | — | |
| SCHEMBL1404091 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL10717084 | 0.90 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL465323 | 0.89 | CHRM2 (0.48) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1404059 | 0.87 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL17817519 | 0.87 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1403835 | 0.87 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28038193 | 0.87 | LMNA (0.65) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| CN-100349854-C | Method for producing (meth) acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| US-7268251-B2 | Method for producing (meth) acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-11 | — | — | US | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-10174349-B2 | Recombinant cell producing 2-hydroxyisobutyric acid | EVONIK ROEHM GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-2291530-B1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK ROEHM GMBH (DE) | 2018-12-26 | — | — | EP | disclosed |
| CN-107083352-A | Produce the recombinant cell of 2 hydroxy-iso-butyric acids | 赢创罗姆有限公司 | 2017-08-22 | — | — | CN | disclosed |
| WO-2017032699-A1 | METHOD FOR PRODUCING LOW-BOILING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2017-03-02 | — | — | WO | disclosed |
| EP-2125771-B1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK ROEHM GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2291530-A1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | Evonik Röhm GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20100029979-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | EVONIK ROEHM GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100010276-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK ROEHM GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009156214-A1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK RÖHM GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
| EP-2125771-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | Evonik Röhm GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2091906-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | Evonik Röhm GmbH (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008061819-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | EVONIK RÖHM GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061821-A1 | PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE | EVONIK RÖHM GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029979-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ACID | MMAB, ASS1, PAM | SMN1; SMN2 3577/4885LMNA 3634/4885ALDH1A1 181/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | SMN1; SMN2 2768/4885LMNA 41/4885ALDH1A1 4315/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | SMN1; SMN2 3845/4885LMNA 4289/4885ALDH1A1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.